GNPX
Genprex, Inc.Substantial doubt about the company's ability to continue as a going concern.
“As a result of its recurring losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern.”View the 10-Q filed May 13, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-04-14 | LONGNECKER BRENT M |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the Reporting Person on April 14, 2026 for tax purposes. |
Common Stock
|
8 |
| 2026-04-14 | LONGNECKER BRENT M |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
Represents shares sold by the Reporting Person on April 14, 2026 for tax purposes. |
Common Stock
(I)
|
10 |
| 2026-02-27 | Berger Mark Stanley |
Chief Medical Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld on February 27, 2026 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025). |
Common Stock
|
7,168 |
| 2026-02-27 | Confer Ryan M. |
Director, President, CEO and CFO |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld on February 27, 2026 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025). |
Common Stock
|
9,330 |
| 2025-12-22 | Berger Mark Stanley |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025, the "EIP") and vests in installments of 50% on February 27, 2026 and the remaining 50% on February 27, 2027, provided that the recipient continues to serve as a Service Provider (as defined in the Company's EIP) through the applicable vesting dates. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. This total represents the number of shares of Common Stock beneficially owned following this reported transaction and the 1-for-50 reverse stock split of the Company's Common Stock effected as of October 21, 2025. |
Common Stock
|
28,500 |
| 2025-12-22 | LONGNECKER BRENT M |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025, the "EIP") and vests 100% upon the earlier of (a) August 15, 2026 and (b) the day prior to the Company's next annual meeting of stockholders occurring after the grant date, provided that the recipient continues to serve as a Service Provider (as defined in the Company's EIP) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. This total represents the number of shares of Common Stock beneficially owned following this reported transaction and the 1-for-50 reverse stock split of the Company's Common Stock effected as of October 21, 2025 (the "RSS"). |
Common Stock
|
9,000 |
| 2025-12-22 | Moreno Toscano Jose Antonio |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025, the "EIP") and vests 100% upon the earlier of (a) August 15, 2026 and (b) the day prior to the Company's next annual meeting of stockholders occurring after the grant date, provided that the recipient continues to serve as a Service Provider (as defined in the Company's EIP) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. This total represents the number of shares of Common Stock beneficially owned following this reported transaction and the 1-for-50 reverse stock split of the Company's Common Stock effected as of October 21, 2025. |
Common Stock
|
9,000 |
| 2025-12-22 | Wilson William R Jr. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025, the "EIP") and vests 100% upon the earlier of (a) August 15, 2026 and (b) the day prior to the Company's next annual meeting of stockholders occurring after the grant date, provided that the recipient continues to serve as a Service Provider (as defined in the Company's EIP) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. This total represents the number of shares of Common Stock beneficially owned following this reported transaction and the 1-for-50 reverse stock split of the Company's Common Stock effected as of October 21, 2025. |
Common Stock
|
9,000 |
| 2025-12-22 | Confer Ryan M. |
Director, President, CEO and CFO |
Award↑
Filing footnotes — Common Stock (Direct)
This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025, the "EIP") and vests in installments of 50% on February 27, 2026 and the remaining 50% on February 27, 2027, provided that the recipient continues to serve as a Service Provider (as defined in the Company's EIP) through the applicable vesting dates. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. This total represents the number of shares of Common Stock beneficially owned following this reported transaction and the 1-for-50 reverse stock split of the Company's Common Stock effected as of October 21, 2025. |
Common Stock
|
45,000 |
| 2025-06-30 | Confer Ryan M. |
Director, President, CEO and CFO |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld on June 30, 2025 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan. |
Common Stock
|
5,775 |
| 2025-06-30 | Berger Mark Stanley |
Chief Medical Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld on June 30, 2025 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan. |
Common Stock
|
4,500 |
| 2025-02-18 | Confer Ryan M. |
Director, President, CEO and CFO |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld on February 18, 2025 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan. |
Common Stock
|
395 |
| 2025-02-18 | Berger Mark Stanley |
Chief Medical Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld on February 18, 2025 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan. |
Common Stock
|
585 |
| 2024-12-05 | Confer Ryan M. |
Director, President, CEO and CFO |
Award↑
Filing footnotes — Common Stock (Direct)
This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests 100% as of June 30, 2025, provided that the recipient continues to serve as a Service Provider (as defined in the Company's 2018 Equity Incentive Plan) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. |
Common Stock
|
29,375 |
| 2024-12-05 | LONGNECKER BRENT M |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests 100% upon the earlier of (a) June 30, 2025 and (b) the day prior to the Company's next annual meeting of stockholders occurring after the grant date, provided that the recipient continues to serve as a Service Provider (as defined in the Company's 2018 Equity Incentive Plan) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. This total represents the amount of securities beneficially owned following this reported transaction and the 1-for-40 reverse stock split of the Company's common stock effected as of February 2, 2024 (the "RSS"). |
Common Stock
|
4,750 |
| 2024-12-05 | Berger Mark Stanley |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests 100% as of June 30, 2025, provided that the recipient continues to serve as a Service Provider (as defined in the Company's 2018 Equity Incentive Plan) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. |
Common Stock
|
18,250 |
| 2024-12-05 | Moreno Toscano Jose Antonio |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests 100% upon the earlier of (a) June 30, 2025 and (b) the day prior to the Company's next annual meeting of stockholders occurring after the grant date, provided that the recipient continues to serve as a Service Provider (as defined in the Company's 2018 Equity Incentive Plan) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. This total represents the amount of securities beneficially owned following this reported transaction and the 1-for-40 reverse stock split of the Company's common stock effected as of February 2, 2024. |
Common Stock
|
4,750 |
| 2024-12-05 | Wilson William R Jr. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests 100% upon the earlier of (a) June 30, 2025 and (b) the day prior to the Company's next annual meeting of stockholders occurring after the grant date, provided that the recipient continues to serve as a Service Provider (as defined in the Company's 2018 Equity Incentive Plan) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. This total represents the amount of securities beneficially owned following this reported transaction and the 1-for-40 reverse stock split of the Company's common stock effected as of February 2, 2024. |
Common Stock
|
4,750 |
| 2024-02-18 | Varner John Rodney |
Director, Chairman, President and CEO |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld on February 18, 2024 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan. This total represents the number of shares of Common Stock directly beneficially owned following this reported transaction and the 1-for-40 reverse stock split of the Company's Common Stock effected as of February 2, 2024 (the "RSS"). |
Common Stock
|
2,642 |
| 2024-02-18 | Berger Mark Stanley |
Chief Medical Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld on February 18, 2024 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan. This total represents the number of shares of Common Stock beneficially owned following this reported transaction and the 1-for-40 reverse stock split of the Company's Common Stock effected as of February 2, 2024. |
Common Stock
|
1,319 |
| 2024-02-18 | Confer Ryan M. |
Director, President, CEO and CFO |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld on February 18, 2024 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan. This total represents the number of shares of Common Stock beneficially owned following this reported transaction and the 1-for-40 reverse stock split of the Company's Common Stock effected as of February 2, 2024. |
Common Stock
|
1,126 |
| 2023-06-27 | Wilson William R Jr. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
This award of Restricted Stock Units ("RSUs") is granted pursuant to the Genprex, Inc. (the "Company") Amended and Restated Outside Director Compensation Policy. One hundred percent (100%) of the RSUs shall vest upon the earlier of (a) the one (1) year anniversary of June 27, 2023 and (b) the day prior to the Company's next annual meeting of stockholders occurring after the grant date, provided that the Outside Director continues to serve as a Service Provider (as defined in the Company's 2018 Equity Incentive Plan) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. |
Common Stock
|
123,795 |
| 2023-06-27 | LONGNECKER BRENT M |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
This award of Restricted Stock Units ("RSUs") is granted pursuant to the Genprex, Inc. (the "Company") Amended and Restated Outside Director Compensation Policy. One hundred percent (100%) of the RSUs shall vest upon the earlier of (a) the one (1) year anniversary of June 27, 2023 and (b) the day prior to the Company's next annual meeting of stockholders occurring after the grant date, provided that the Outside Director continues to serve as a Service Provider (as defined in the Company's 2018 Equity Incentive Plan) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. |
Common Stock
|
123,795 |
| 2023-06-27 | Moreno Toscano Jose Antonio |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
This award of Restricted Stock Units ("RSUs") is granted pursuant to the Genprex, Inc. (the "Company") Amended and Restated Outside Director Compensation Policy. One hundred percent (100%) of the RSUs shall vest upon the earlier of (a) the one (1) year anniversary of June 27, 2023 and (b) the day prior to the Company's next annual meeting of stockholders occurring after the grant date, provided that the Outside Director continues to serve as a Service Provider (as defined in the Company's 2018 Equity Incentive Plan) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. |
Common Stock
|
123,795 |
| 2023-04-21 | Varner John Rodney |
Director, Chairman, President and CEO |
Buy↑
Filing footnotes — Common Stock (Indirect)
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.0299 to $1.07 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
(I)
|
19,000 |
| 2023-04-21 | VACZY CATHERINE M |
EVP GC Chief Strategy Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.06 to $1.08 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
20,000 |
| 2023-02-18 | Kumar Hermant |
Chief Mfgr & Tech Officer |
Award↑
Filing footnotes — Common Stock (Direct)
This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests in installments of 50% on the first anniversary of the date of grant and the remaining 50% on the second anniversary of the date of grant. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. |
Common Stock
|
200,000 |
| 2023-02-18 | Varner John Rodney |
Director, Chairman, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests in installments of 50% on the first anniversary of the date of grant and the remaining 50% on the second anniversary of the date of grant. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value ("Common Stock") on a one-to-one basis. This total now excludes 10,000 shares of Common Stock that were previously reported as being purchased on March 29, 2018 and directly held by Reporting Person. The prior inclusion of these shares was inadvertent and due to an administrative error. |
Common Stock
|
625,000 |
| 2023-02-18 | Berger Mark Stanley |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests in installments of 50% on the first anniversary of the date of grant and the remaining 50% on the second anniversary of the date of grant. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. |
Common Stock
|
245,000 |
| 2023-02-18 | VACZY CATHERINE M |
EVP GC Chief Strategy Officer |
Award↑
Filing footnotes — Common Stock (Direct)
This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests in installments of 50% on the first anniversary of the date of grant and the remaining 50% on the second anniversary of the date of grant. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. |
Common Stock
|
245,000 |
| 2023-02-18 | Confer Ryan M. |
Director, President, CEO and CFO |
Award↑
Filing footnotes — Common Stock (Direct)
This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests in installments of 50% on the first anniversary of the date of grant and the remaining 50% on the second anniversary of the date of grant. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. |
Common Stock
|
245,000 |
| 2022-07-28 | Confer Ryan M. |
Director, President, CEO and CFO |
Convert↑
|
Common Stock
|
116,973 |
| 2022-07-28 | Confer Ryan M. |
Director, President, CEO and CFO |
Convert↓
|
Stock Option (right to buy)
|
116,973 |
| 2022-06-23 | Wilson William R Jr. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Equal to the fair market value of a share of common stock on June 23, 2022, the date on which the option grant was made under the Genprex, Inc. Outside Director Compensation Policy. One hundred percent (100%) of the Shares subject to the Option shall vest upon the earlier of (a) the one (1) year anniversary of June 23, 2022 and (b) the day prior to the Company's next annual meeting of the Company's stockholders occurring after the grant date, provided that the Optionee continues to serve as a Service Provider (as defined in the Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date. |
Stock Option (right to buy)
|
83,368 |
| 2022-06-23 | LONGNECKER BRENT M |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Equal to the fair market value of a share of common stock on June 23, 2022, the date on which the option grant was made under the Genprex, Inc. Outside Director Compensation Policy. One hundred percent (100%) of the Shares subject to the Option shall vest upon the earlier of (a) the one (1) year anniversary of June 23, 2022 and (b) the day prior to the Company's next annual meeting of the Company's stockholders occurring after the grant date, provided that the Optionee continues to serve as a Service Provider (as defined in the Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date. |
Stock Option (right to buy)
|
83,368 |
| 2022-06-23 | Moreno Toscano Jose Antonio |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Equal to the fair market value of a share of common stock on June 23, 2022, the date on which the option grant was made under the Genprex, Inc. Outside Director Compensation Policy. One hundred percent (100%) of the Shares subject to the Option shall vest upon the earlier of (a) the one (1) year anniversary of June 23, 2022 and (b) the day prior to the Company's next annual meeting of the Company's stockholders occurring after the grant date, provided that the Optionee continues to serve as a Service Provider (as defined in the Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date. |
Stock Option (right to buy)
|
83,368 |
| 2022-06-23 | Kumar Hermant |
Chief Mfgr & Tech Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
One third (1/3) of the Shares subject to the Option shall vest on each annual anniversary of June 23, 2022 so that one hundred percent (100%) of the shares subject to the Option are vested on the third anniversary of June 23, 2022 provided that the optionee continues to serve as a Service Provider (as defined in Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date. |
Stock Option (right to buy)
|
75,000 |
| 2022-02-04 | Varner John Rodney |
Director, Chairman, President and CEO |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option (the "Option") was granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (the "Plan"). The Option shall vest and become exercisable as to one third (1/3) of the total number of shares (the "Shares") of the Company's common stock, $.001 par value subject to the Option on February 4, 2023 (the "Vesting Commencement Date") and thereafter shall vest and become exercisable as to an additional 1/24 of the remaining Shares subject to the Option on each monthly anniversary of the Vesting Commencement Date until fully vested and exercisable, in each case provided that the Optionee continues to serve as a Service Provider (as defined in the Plan) through the applicable vesting date. |
Stock Option (right to buy)
|
1,062,250 |
| 2022-02-04 | VACZY CATHERINE M |
EVP GC Chief Strategy Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option (the "Option") was granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (the "Plan"). The Option shall vest and become exercisable as to one third (1/3) of the total number of shares (the "Shares") of the Company's common stock, $.001 par value subject to the Option on February 4, 2023 (the "Vesting Commencement Date") and thereafter shall vest and become exercisable as to an additional 1/24 of the remaining Shares subject to the Option on each monthly anniversary of the Vesting Commencement Date until fully vested and exercisable, in each case provided that the Optionee continues to serve as a Service Provider (as defined in the Plan) through the applicable vesting date. |
Stock Option (right to buy)
|
325,000 |
| 2022-02-04 | Berger Mark Stanley |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option (the "Option") was granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (the "Plan"). The Option shall vest and become exercisable as to one third (1/3) of the total number of shares (the "Shares") of the Company's common stock, $.001 par value subject to the Option on February 4, 2023 (the "Vesting Commencement Date") and thereafter shall vest and become exercisable as to an additional 1/24 of the remaining Shares subject to the Option on each monthly anniversary of the Vesting Commencement Date until fully vested and exercisable, in each case provided that the Optionee continues to serve as a Service Provider (as defined in the Plan) through the applicable vesting date. |
Stock Option (right to buy)
|
98,750 |
| 2022-02-04 | Kumar Hermant |
Chief Mfgr & Tech Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option (the "Option") was granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (the "Plan"). The Option shall vest and become exercisable as to one third (1/3) of the total number of shares (the "Shares") of the Company's common stock, $.001 par value subject to the Option on February 4, 2023 (the "Vesting Commencement Date") and thereafter shall vest and become exercisable as to an additional 1/24 of the remaining Shares subject to the Option on each monthly anniversary of the Vesting Commencement Date until fully vested and exercisable, in each case provided that the Optionee continues to serve as a Service Provider (as defined in the Plan) through the applicable vesting date. |
Stock Option (right to buy)
|
54,312 |
| 2022-02-04 | Confer Ryan M. |
Director, President, CEO and CFO |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option (the "Option") was granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (the "Plan"). The Option shall vest and become exercisable as to one third (1/3) of the total number of shares (the "Shares") of the Company's common stock, $.001 par value subject to the Option on February 4, 2023 (the "Vesting Commencement Date") and thereafter shall vest and become exercisable as to an additional 1/24 of the remaining Shares subject to the Option on each monthly anniversary of the Vesting Commencement Date until fully vested and exercisable, in each case provided that the Optionee continues to serve as a Service Provider (as defined in the Plan) through the applicable vesting date. |
Stock Option (right to buy)
|
341,750 |
| 2021-09-27 | Berger Mark Stanley |
Chief Medical Officer |
Other↑
|
No Securities Owned
|
0 |
| 2021-09-27 | Kumar Hermant |
Chief Mfgr & Tech Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options were granted outside of the Registrant's incentive award plans as an inducement grant pursuant to Nasdaq Listing Rule 5635(c)(4). One-third of the options will vest on each of the first, second and third anniversaries of the date on which the Reporting Person commences employment with the Registrant. |
Stock Option (right to buy)
|
400,000 |
| 2021-09-27 | Berger Mark Stanley |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The options were granted outside of the Registrant's incentive award plans as an inducement grant pursuant to Nasdaq Listing Rule 5635(c)(4). One-third of the options will vest on each of the first, second and third anniversaries of the date on which the Reporting Person commences employment with the Registrant. |
Stock Option (right to buy)
|
550,000 |
| 2021-09-27 | Kumar Hermant |
Chief Mfgr & Tech Officer |
Other↑
|
No Securities Owned
|
0 |
| 2021-06-24 | LONGNECKER BRENT M |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Equal to the fair market value of a share of common stock on June 24, 2021, the date on which the option grant was made under the Genprex, Inc. Outside Director Compensation Policy. One hundred percent (100%) of the Shares subject to the Option shall vest upon the earlier of (a) the one (1) year anniversary of June 24, 2021 and (b) the day prior to the Company's next annual meeting of the Company's stockholders occurring after the grant date, provided that the Optionee continues to serve as a Service Provider (as defined in the Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date. |
Stock Option (right to buy)
|
32,376 |
| 2021-06-24 | Moreno Toscano Jose Antonio |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Equal to the fair market value of a share of common stock on June 24, 2021, the date on which the option grant was made under the Genprex, Inc. Outside Director Compensation Policy. One hundred percent (100%) of the Shares subject to the Option shall vest upon the earlier of (a) the one (1) year anniversary of June 24, 2021 and (b) the day prior to the Company's next annual meeting of the Company's stockholders occurring after the grant date, provided that the Optionee continues to serve as a Service Provider (as defined in the Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date. |
Stock Option (right to buy)
|
32,376 |
| 2021-06-24 | Wilson William R Jr. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Equal to the fair market value of a share of common stock on June 24, 2021, the date on which the option grant was made under the Genprex, Inc. Outside Director Compensation Policy. One hundred percent (100%) of the Shares subject to the Option shall vest upon the earlier of (a) the one (1) year anniversary of June 24, 2021 and (b) the day prior to the Company's next annual meeting of the Company's stockholders occurring after the grant date, provided that the Optionee continues to serve as a Service Provider (as defined in the Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date. |
Stock Option (right to buy)
|
32,376 |
| 2021-04-05 | LONGNECKER BRENT M |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported is a weighted average price. A total of 15,000 shares were purchased in multiple transactions at prices ranging from $4.1375 per share to $4.16 per share. |
Common Stock
|
15,000 |